Skip to content
Life Sciences Series A Founded 2011

OncoStem

OncoStem develops prognostic tests for cancer detection. Its flagship product CanAssist-Breast uses a proprietary AI-based statistical model to identify patient risk of breast cancer recurrence, providing additional tumor information for customized cancer treatment. Founded in 2011 in Bengaluru, India, the company has raised $9.0M in Series A funding from investors including Artiman and Peak XV Partners. Developer…

📍 Bengaluru, India · Oncology,

Funding snapshot

Last roundSeries A
Amount$6M
Date6 September 2017
Total raised$9M
Team size18

About

OncoStem develops prognostic tests for cancer detection. Its flagship product CanAssist-Breast uses a proprietary AI-based statistical model to identify patient risk of breast cancer recurrence, providing additional tumor information for customized cancer treatment. Founded in 2011 in Bengaluru, India, the company has raised $9.0M in Series A funding from investors including Artiman and Peak XV Partners. Developer of prognostic tests for the detection of cancer. The company's flagship product is CanAssist-Breast, which uses a proprietary Artificial Intelligence-based statistical model to identify the patient's risk of breast cancer recurrence. Also, it provides additional information about the tumor, based on which the cancer treatment can be customized. Founded in 2011, headquartered in Bengaluru, India.

Business model

Oncology > In-Vitro Diagnostic Tests > Women's Cancer > Breast Cancer > Prognosis,

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Precision Medicine

Team background

College Wise > Indian Institute of Science

Institutional investors

Artiman Peak XV Partners Springboard Enterprises

Latest coverage

No articles yet.

Raising like OncoStem?

Analyze your pitch deck before your next raise.

Analyze My Deck →